SNT 8.33% 3.9¢ syntara limited

Ann: Boehringer Ingelheim discontinues development of BI 1467335, page-5

  1. 27 Posts.
    so they say in the announcement they are now looking forward to the FDA decision on Bronchitol and the focus now is on the anti cancer lox inhibitor program.

    So I guess a potential LOXL2 sale is dead and buried as well, no mention of the usual blurb about "progressing potential partners for LOXL2..... another fail I guess that no one wants it after nearly 2 years on the market.
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.